ZTS - Zoetis (ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets – Hagens Berman | Benzinga

SAN FRANCISCO, May 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman is urging investors who suffered substantial losses in Zoetis Inc. (NYSE:ZTS) to promptly report their losses here. Additionally, individuals with relevant knowledge who may assist in the investigation are encouraged to contact the firm's attorneys.

Website: www.hbsslaw.com/investor-fraud/ZTS
Contact the Firm Now: ZTS@hbsslaw.com Phone: 844-916-0895

Zoetis Inc. (ZTS) Investigation:

The investigation centers around Zoetis' arthritis drugs, specifically Librela™ and Solensia™, which are designed to alleviate painful osteoarthritis in dogs and cats, respectively.

Historically, these products have been significant revenue drivers for Zoetis' companion animal division, with the company projecting peak sales ...

ZTS) Stock Declines Amid Concerns Over Arthritis Drugs Impacting Pets – Hagens Berman>Full story available on Benzinga.com